Mounjaro vs Ozempic: Tirzepatide vs Semaglutide for Diabetes and Weight Loss
Among patients searching for the most effective injectable for diabetes or weight loss, the Mounjaro vs Ozempic question is one of the most-searched in cash-pay healthcare. The SURPASS-2 head-to-head trial published in NEJM provides the cleanest direct comparison: tirzepatide outperforms semaglutide on both A1c reduction and weight loss outcomes in patients with type 2 diabetes.
At a Glance
| Dimension | Tirzepatide for Weight Loss | Semaglutide for Weight Loss |
|---|---|---|
| Active ingredient | Tirzepatide (dual GLP-1/GIP agonist) | Semaglutide (single GLP-1 agonist) |
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA approval (diabetes) | May 2022 | December 2017 |
| Maximum dose (diabetes) | 15 mg/week | 2.0 mg/week |
| Average A1c reduction (SURPASS-2) | −2.30% | −1.86% |
| Average weight loss (head-to-head) | ~25 lbs at 40 weeks | ~14 lbs at 40 weeks |
| Retail price (US, 2026) | $1,070-$1,200/month | $1,030/month |
| GI side effect rates | Similar - nausea 30-40% | Similar - nausea 30-45% |
| Cardiovascular outcomes data | SURPASS-CVOT pending (2025-2026) | SUSTAIN-6, REWIND, SELECT trials positive |
| Weight loss labeled brand | Zepbound (same molecule) | Wegovy (same molecule) |
About this comparison
Mounjaro (tirzepatide) and Ozempic (semaglutide) are both FDA-approved for type 2 diabetes and commonly used off-label for weight loss. Mounjaro is a dual GLP-1/GIP agonist; Ozempic is a single GLP-1 agonist. The SURPASS-2 head-to-head trial demonstrated tirzepatide produces greater weight loss and greater A1c reduction than semaglutide in type 2 diabetes patients. Tirzepatide is the newer molecule with growing market share.
Patients with type 2 diabetes seeking maximum A1c reduction and weight loss. Patients who have plateaued on semaglutide. Patients who can afford brand pricing or have insurance coverage for Mounjaro. The slightly greater efficacy makes Mounjaro the preferred starting choice for many endocrinologists in 2026.
Patients with established cardiovascular disease (semaglutide has the SELECT trial cardiovascular outcomes evidence). Patients whose insurance covers Ozempic but not Mounjaro. Patients with milder diabetes where the slight efficacy advantage of tirzepatide is less important. Patients in markets where Ozempic supply is more reliable.
Cost comparison
Mounjaro and Ozempic have similar retail pricing ($1,030-$1,200/month). Insurance coverage is the primary cost driver: both are broadly covered for type 2 diabetes. Compounded versions follow similar pricing: compounded semaglutide $199-$499/month, compounded tirzepatide $250-$600/month. Mounjaro produces 1.5-2x the weight loss; cost per pound lost typically favors Mounjaro.
Evidence comparison
SURPASS-2 trial (NEJM 2021) directly compared the two drugs in type 2 diabetes: tirzepatide produced superior A1c reduction and weight loss across all tested doses. SUSTAIN-6 (semaglutide) and SELECT (semaglutide in obesity) provide the strongest cardiovascular outcomes evidence to date. Tirzepatide cardiovascular outcomes (SURPASS-CVOT) are pending. Both are well-tolerated.
Frequently asked questions
Is Mounjaro more effective than Ozempic? +
Yes, in the SURPASS-2 head-to-head trial published in the New England Journal of Medicine, tirzepatide produced greater A1c reduction (-2.30% vs -1.86%) and greater weight loss (approximately 25 lbs vs 14 lbs at 40 weeks) than semaglutide in type 2 diabetes patients. Tirzepatide is the more powerful of the two drugs in direct comparison.
Why might my doctor prefer Ozempic over Mounjaro? +
Insurance coverage and formulary placement vary by plan. Some plans cover one but not the other. Doctors also consider individual factors: established cardiovascular disease favors semaglutide (SELECT trial). Patients who have done well on semaglutide and reached goals do not need to switch. Supply availability has also varied over 2022-2026.
Can I switch from Ozempic to Mounjaro? +
Yes. The standard approach is to stop Ozempic for 1 week, then start Mounjaro at the lowest dose (2.5 mg) and titrate up every 4 weeks. Some clinicians use shorter washouts. Discuss with your prescribing provider.
Which has worse side effects, Mounjaro or Ozempic? +
Side effect profiles are very similar - both cause GI side effects (nausea, constipation, diarrhea) primarily during dose titration. Individual variation is substantial. Patients who tolerate one well typically tolerate the other; patients who do poorly on one may benefit from switching.
Are Mounjaro and Zepbound the same drug? +
Yes, both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management. Same molecule, different labeled indications, different maximum doses (Mounjaro 15 mg/week, Zepbound 15 mg/week as well).
Is Mounjaro covered by Medicare? +
Medicare Part D covers Mounjaro for type 2 diabetes (its labeled indication). Medicare does not cover Zepbound (tirzepatide for obesity). Same molecule, different coverage based on indication.
Can I get compounded Mounjaro? +
Compounded tirzepatide was widely available 2022-2024 during the FDA shortage period. Following the October 2024 FDA shortage resolution, compounding pathways have tightened. Some 503A pharmacies continue to compound tirzepatide; verify FDA-approved API source.
Which is better for cardiovascular disease, Mounjaro or Ozempic? +
Semaglutide currently has stronger cardiovascular outcomes evidence (SELECT trial: 20% reduction in major cardiovascular events). Tirzepatide cardiovascular outcomes (SURPASS-CVOT) are still being studied (results expected 2025-2026). For patients with established cardiovascular disease, semaglutide has the stronger evidence-based case in 2026.
Bottom line
For most type 2 diabetes patients in 2026, Mounjaro is the marginally more effective choice if insurance covers it. For patients with established cardiovascular disease, semaglutide retains the cardiovascular outcomes evidence advantage until SURPASS-CVOT reads out. Both are dramatic improvements over older diabetes options.
Sources
- Frias JP, et al. SURPASS-2 trial. New England Journal of Medicine, 2021. (Head-to-head tirzepatide vs semaglutide)
- Lincoff AM, et al. SELECT trial. NEJM, 2023. (Semaglutide cardiovascular outcomes)
- FDA. Mounjaro Prescribing Information. 2024. (Mounjaro labeling)
- FDA. Ozempic Prescribing Information. 2024. (Ozempic labeling)